Cord blood stem cells trialed for autism – but Don't get your hopes up yet

NCT ID NCT07622316

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether a combination of umbilical cord stem cells and glutathione can safely improve autism symptoms in 100 people aged 3 and older. Participants receive either the stem cell product plus glutathione, or a placebo plus glutathione, with the option to switch groups later. The main goal is to check safety and see if symptoms improve on a standard autism checklist. However, the treatment is not FDA-approved, costs $12,000, and this early-stage trial cannot guarantee any benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
umbilical cord blood-derived stem cells and exosomes (AdiaVita) plus glutathione
What this could lead to
If it works, this could point toward a treatment that reduces autism symptoms for some children and adults.
What could go wrong
This is a very early Phase 1 trial focused on safety, not proof of effectiveness. The treatment is not FDA-approved for autism, costs $12,000, and carries risks like infusion reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Greater Atlanta Integrative Pediatrics

    RECRUITING

    Roswell, Georgia, 30076, United States

  • Greater Atlanta Integrative Pediatrics

    RECRUITING

    Roswell, Georgia, 30076, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.